Last checked at 23 Oct 2019 09:32
ReNeuron Shares Jump As Lead Cell Line Shows Further Potential
ReNeuron Shares Jump As Lead Cell Line Shows Further Potential
Read more
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- Stock Screeners
- Share Chat
- FX
- News & RNS
- Events
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Reneuron Share News (RENE)
RENE Share
Price
RENE Share
News
RENE Share
Chat
RENE Share
Trades
RENE
Live RNS
RENE Share
Charts
RENE Level 2
Console
RENE Live
Share Price
RENE Broker
Ratings
RENE Directors
Deals
RENE Financial
Diary
RENE
Fundamentals
RENE Short
Positions
RENE
Media
Reneuron Information
- This share is currently suspended. It was suspended at a price of 3.275
Share Price Information for Reneuron (RENE)
Share Price is delayed by 15 minutes
Get Live Data
Share Price:
3.275
Bid:
0.00
Ask:
0.00
Change:
0.00 (0.00%)
Spread:
0.00 (0.00%)
Open:
0.00
High:
0.00
Low:
0.00
Prev. Close:
3.275
Last checked at -
Watchlists are a member only feature
Login to your account
Don't have an account? Click here to register.ReNeuron wins 'Breakthrough of the Year' at European Mediscience Awards
Fri, 14th Jun 2019 15:49
(Sharecast News) - Cell-based therapeutics developer ReNeuron Group has won the 'Breakthrough of the Year' award at the 2019 European Mediscience Awards, it announced on Friday.The AIM-traded firm said the award underlined the "strong clinical development and commercial progress" it had made over the last 12 months.That included positive data from the ongoing phase 1 and 2a clinical trial in retinitis pigmentosa, and the signing of an exclusive licence agreement with Shanghai Fosun Pharmaceutical Industrial Development Company for the development, manufacture and commercialisation of ReNeuron's CTX and hRPC cell therapy programmes in the People's Republic of China."We are delighted to have been awarded the Breakthrough of the Year award at the 2019 European Mediscience Awards," said ReNeuron chief executive officer Olav Hellebø."We are greatly encouraged by the progress we have made with our cell therapy clinical development programmes for retinitis pigmentosa and stroke disability over the past year and look forward to continuing to advance our clinical and business development activities in the months ahead."
More News
2 Oct 2019 15:15
ReNeuron Reports Mixed Results For Retinitis Pigmentosa Trial
ReNeuron Reports Mixed Results For Retinitis Pigmentosa Trial
Read more21 Aug 2019 11:49
ReNeuron boosts scientific advisory board with three appointments
(Sharecast News) - Cell-based therapeutics developer ReNeuron Group announced the appointment of professor Robert MacLaren, Dr Sally Temple and Dr José-Alain Sahel to its scientific advisory board on Wednesday.
Read more14 Aug 2019 15:35
ReNeuron's New Cardiff University Venture Gets Research Grant
(Alliance News) - ReNeuron Group PLC on Wednesday said a new venture with Cardiff University has secured a UK government grant to research and develop new treatments for hard-to-target disorders a
Read more14 Aug 2019 11:16
ReNeuron enters grant-funded partnership with University of Cardiff
(Sharecast News) - Cell-based therapeutics developer ReNeuron Group is partnering with the University of Cardiff under a new grant-funded collaboration utilising its exosome-based drug delivery technology platform, it announced on Wednesday.
Read more16 Jul 2019 12:16
ReNeuron Secures Patents For Its Exosome Technology Platform
(Alliance News) - ReNeuron Group PLC on Tuesday said it has expanded its intellectual property estate via the grant of patents, covering its exosome technology platform.The cell-based said
Read more11 Jul 2019 11:36
ReNeuron Annual Loss Narrows On Finance Income And Licence Fee
(Alliance News) - ReNeuron Group PLC on Thursday said its loss narrowed in its most recent financial year after it received an exclusivity fee and increased finance income.Shares in were at
Read more8 May 2019 11:19
ReNeuron Expects Annual Results In Line With Views After Progress
LONDON (Alliance News) - ReNeuron Group PLC on Wednesday said it expects its annual results to be in line with the board's expectations as it made progress on several clinical cell-based also
Read more8 May 2019 08:53
ReNeuron advances blindness and stroke therapy candidates
(Sharecast News) - Therapeutics outfit ReNeuron continued to trade in line with expectations throughout its recently wrapped up trading year, advancing both its human retinal progenitor cell therapy candidate and its CTX cell therapy candidate.
Read more26 Apr 2019 12:09
ReNeuron upbeat on early data from retinitis pigmentosa trials
(Sharecast News) - Cell-based therapeutics developer ReNeuron Group announced updated positive preliminary data in its ongoing phase 1 and 2a clinical trial of its human retinal progenitor cell (hRPC) therapy candidate in the blindness-causing disease, retinitis pigmentosa (RP), on Friday.
Read more26 Apr 2019 09:58
ReNeuron Reports Positive Test Results For Blindness Treatment Therapy
LONDON (Alliance News) - ReNeuron Group PLC on Friday reported positive trial results for its human retinal progenitor cell therapy candidate for treating blindness-causing disease retinitis in up
Read more11 Apr 2019 18:24
DIRECTOR DEALINGS: ReNeuron Chair And Other Board Members Buy Shares
LONDON (Alliance News) - ReNeuron Group PLC said a number of directors purchased shares on Thursday, including Non-Executive Chair John Berriman who bought 80,000 shares at 225 pence Thursday, in
Read more9 Apr 2019 10:55
ReNeuron Signs Licence Deal For CTX, hRPC Cell Programmes In China
LONDON (Alliance News) - ReNeuron Group PLC on Tuesday said it has signed an exclusive licence agreement for the development, manufacture and commercialisation of its CTX and hRPC cell therapy in
Read more4 Apr 2019 14:19
ReNeuron upbeat on progress in hRPC study
(Sharecast News) - Cell-based therapeutics developer ReNeuron Group updated the market on progress with its ongoing phase 1 and 2 clinical trial in the US of its 'hRPC' cell therapy candidate in the blindness-causing disease retinitis pigmentosa (RP) on Thursday, confirming that the positive efficacy seen and previously announced had, to date, been sustained in the first patient cohort in the phase 2 part of the study.
Read more